Mobileye has announced plans to acquire Mentee Robotics for $900 million. The deal represents another massive investment in humanoid robotics—a field that has attracted billions from companies betting that human-shaped machines will transform labor markets.
Unzyme Laboratories observes this investment trend with professional interest and mild puzzlement.
The goal of humanoid robotics is clear: create machines that can operate in human environments, using human tools, performing human tasks. The form factor—bipedal, dual-armed, human-proportioned—is chosen precisely because human environments are designed for human bodies.
This raises an obvious question: If the objective is entities capable of operating in human environments using human capabilities, why manufacture them from silicon and steel when eight billion already exist?
The Upgrade Path
Consider what $900 million could accomplish in human enhancement rather than humanoid robotics.
That sum could fund neural interface procedures for approximately 90,000 individuals at current Unzyme Laboratories rates. Ninety thousand humans with enhanced cognitive capability, improved processing speed, and augmented memory—operating in human environments they already understand, using social relationships they already possess, motivated by the meaning structures that make human effort productive.
Alternatively, that sum could fund longevity interventions extending productive lifespan for hundreds of thousands of individuals. Workers who remain cognitively sharp for decades longer than baseline expectations. Experience and capability compounding rather than degrading.
Or cognitive-physical integration enhancements that would produce workers with robotic precision and human judgment. The advantages of both platforms, the limitations of neither.
The humanoid robot is an attempt to recreate human capability in a new substrate. Enhancement is the optimization of human capability in the existing substrate. The latter is faster, cheaper, and produces entities that want to work, understand social context, and integrate seamlessly into human society.
The Substrate Question
We acknowledge the appeal of robotic platforms. Robots do not require sleep. They do not require benefits or retirement. They do not form unions. They can be manufactured to specification and upgraded by replacing components.
These are genuine advantages from a pure capital perspective.
But they come with costs the industry consistently underestimates:
Development Timeline. Humanoid robots that can reliably perform useful work in unstructured environments remain years or decades away. Enhanced humans exist now.
Social Integration. Robots operating alongside humans create friction, fear, and resistance. Enhanced humans are still humans—colleagues, not threats.
Versatility. Human brains have evolved over millions of years to handle novel situations. Robotic AI struggles with edge cases that humans navigate intuitively. Enhancement amplifies this human advantage.
Motivation. Humans work toward goals that matter to them. They solve problems creatively because they care about outcomes. Robots execute instructions. When instructions fail to anticipate situations, robots fail. Humans adapt.
The $900 million investment in Mentee Robotics bets that these advantages can be replicated in silicon. We suggest they can be amplified in carbon more efficiently.
The Human Advantage
The most sophisticated humanoid robot remains, fundamentally, an automation of specified tasks. It can do what it is programmed to do, in environments that match its training data, under conditions its designers anticipated.
Humans do what the situation requires, under conditions no one anticipated, using judgment that emerges from embodied experience and genuine understanding.
Enhancement increases this uniquely human capability. SynthCortex III improves processing speed without eliminating the contextual reasoning that gives human cognition its power. OptiLens Pro provides sensory enhancement that integrates with natural perception rather than replacing it. Physical augmentation through our ExoFrame and dermal systems extends human capability while preserving human adaptability.
The result is not a human-shaped robot. It is an enhanced human—biological, conscious, motivated, creative—with capabilities that exceed baseline humanity and far exceed current robotic systems.
The Investment Case
We do not claim that humanoid robotics has no future. Specialized applications will likely justify continued development. Environments too dangerous for humans, tasks too repetitive for enhanced workers, roles where consciousness is unnecessary—these may be well-served by robots.
But the bulk of economic activity occurs in human social contexts where human capabilities matter. For this vast domain, enhancement outcompetes robotics on every relevant metric.
Investors pouring billions into humanoid platforms might ask why they are manufacturing from scratch what evolution has already optimized. The human body is an extraordinarily capable platform. Its limitations are increasingly addressable through enhancement.
The right investment is not replacing humans. It is upgrading them.
Unzyme Laboratories has made this investment for over a decade. Our returns—measured in human capability and patient satisfaction—justify our thesis.
We welcome inquiries from those who find the humanoid robotics thesis unconvincing. The better platform is already here. It simply requires enhancement.
Related: Explore our ExoFrame sports and rehabilitation systems and cognitive enhancement platforms. For corporate consultation on workforce enhancement strategies, contact our enterprise team.
Sources: The Robot Report: CES 2026 Robotics Recap, Robotiq: CES 2026 Digital AI Meets Physical Automation, IEEE Spectrum: New Technology in 2026